Medix Biochemica, a supplier of critical raw materials for the in vitro diagnostics (IVD) industry, has acquired Candor Bioscience GmbH, a Germany-based developer and manufacturer of premium immunoassay solutions.

The acquisition strengthens Medix Biochemica’s range of high-quality raw materials and enhances its capabilities to support test manufacturers in immunoassay development. Following the transaction, Candor Bioscience’s operations will remain in Germany.

“We are delighted to welcome Candor into the Medix Biochemica family. The partnership with Candor strengthens Medix Biochemica’s ability to support our customer base by adding complementary expertise in immunoassay development and broadening our offering of critical IVD raw materials with a leading portfolio of premium blockers and stabilizers. Together, we will continue to provide the highest quality raw materials that enable diagnostic innovation, and we look forward to a successful collaboration with the Candor team,” said Steve Ferguson, CEO of Medix Biochemica.

Dr. Tobias Polifke and Dr. Peter Rauch, co-founders and Managing Directors of Candor Bioscience, remarked: “Joining forces with Medix Biochemica is an exciting milestone for Candor. We are proud of our legacy in providing differentiated, high-performance solutions for immunoassay development, and we share Medix Biochemica’s commitment to quality and innovation. By combining our capabilities and offerings, we will be better positioned to support the evolving needs of our customers. Medix Biochemica’s products, including antibodies and quality control materials, perfectly complement our solutions, enhancing the value we offer to partners in the IVD industry.”